The new guidance for operating cash burn excluding collaborative revenue from NVS (effectively reimbursement for MNTA’s R&D) and excluding MNTA’s small Lovenox royalty payable to MIT is $22-28M per quarter.
The above guidance includes an unspecified amount for MNTA’s portion of ongoing legal fees for the Lovenox patent case. (NVS pays 100% of the ongoing legal fees in the Copaxone patent case.)
Market Data 
Markets 
AI
